title: The future of non-human primate use in mAb development.
abstract: It has been predicted that the use of non-human primates (NHPs) is going to increase considerably in the development of monoclonal antibodies (mAbs). Opportunities exist to focus on a rigorous, science-based approach to drug development, however, which will minimize this increase. In this article, the authors review current and future NHP use in mAb development based on surveys, experience and expert opinion and propose a framework that will minimize future NHP use and continue to support science and innovation.
authors.affiliation: National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK. kathryn.chapman@nc3rs.org.uk
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Chapman
authors.forename: Nick
authors.initials: N
authors.lastname: Pullen
authors.forename: Laura
authors.initials: L
authors.lastname: Andrews
authors.forename: Ian
authors.initials: I
authors.lastname: Ragan
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D005544:Forecasting; D006801:Humans; D008252:Macaca fascicularis
chemical_list: D000911:Antibodies, Monoclonal